DOCSLIB.ORG

Novel Psychoactive Substances Certified Reference Materials for Forensic Analysis, Clinical Toxicology & Drug Testing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Novel Psychoactive Substances Certified Reference Materials for Forensic Analysis, Clinical Toxicology & Drug Testing Novel Psychoactive Substances Certified Reference Materials for Forensic Analysis, Clinical Toxicology & Drug Testing Reference Materials for accurate results The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Table of contents Reference Materials for Novel Psychoactive Substances Amphetamines ..................................................4 Analgesics (non-opioid) ......................................6 Benzodiazepines ................................................7 Benzyl & Phenyl Piperazines ................................9 Synthetic Cannabinoids .................................... 10 Cathinones ..................................................... 12 Cocaine analogues ........................................... 14 Fentanyls ....................................................... 15 Hallucinogens ................................................. 17 Opiates & Opioids ............................................ 18 Phenethylamines ............................................. 19 Pipradrols & Piperidines .................................... 19 2 SigmaAldrich.com/cerilliant Consistency is Our Standard. We produce reference materials! balances that have been qualified to ensure minimal Not research chemicals! uncertainty, flame sealed under argon into ampoules for long term shelf life and are rigorously tested Novel Psychoactive Substances (NPS) are newly through accelerated and real time studies to ensure misused narcotic or psychotropic compounds, accuracy and shelf life. These solution-based CRMs comparable to classic psychotropic substances, that are suitable for numerous applications from forensic may pose a threat to public health. NPS drugs are analysis, clinical toxicology, urine drug testing, typically analogs and synthetic derivatives of naturally or pharmaceutical research to pain management occurring compounds, existing controlled substances, and prescription monitoring. They can be used as or research chemicals used during the development of calibrators and controls or for quantitation, including pharmaceuticals, designed to produce effects similar isotope dilution methods by GC/MS or LC/MS. Since to the controlled substances they mimic. Illicit and many NPS are classified as controlled substances, legal sources of NPS promote them as “legal highs”, Cerilliant® solution-based certified reference materials “research chemicals”, and “designer drugs” or as are offered in a convenient, DEA-exempt format products labeled “not for human consumption”, “plant designed to improve laboratory efficiency. food” or “bath salts” to circumvent regulations. NPS ® are diverse and include many drug classes, such as Cerilliant certified solution standards and Certified ® amphetamines, analgesics, benzodiazepines, benzyl Spiking Solutions are manufactured and tested to the & phenyl piperazines, cannabinoids, cathinones, highest industry standards including ISO 17034, cocaine analogs, fentanyls, hallucinogens, opiates and ISO/IEC 17025, ISO 13485 and ISO 9001. Each opioids, phenethylamines, pipradrols and piperidines, certified reference material is supported by a and a range of prescribed medications. NPS drugs comprehensive Certificate of Analysis which provides are currently emerging at an unprecedented rate all analytical data on stability, homogeneity, accuracy worldwide. of concentration as compared to an independently prepared multi-point calibration curve, and uncertainty and traceability information to support regulatory Our high standards match yours requirements. ® Our Cerilliant brand offers the widest selection of Cerilliant® CRM are designed to promote laboratory high-quality Certified Reference Materials (CRMs) for efficiency, ensure accuracy and reliability of results and novel psychoactive substances including parent drugs, support laboratory regulatory requirements. We provide metabolites, impurities, and degradants, as well as accurate reference materials, saving you from doubt their stable-labeled internal standards. These certified and uncontrolled uncertainty caused by the use of reference materials are fully characterized under research grade chemicals for with calibration. ISO/IEC 17025 and ISO 17034 accreditation; their solutions are gravimetrically prepared using precision We know only the most accurate and reliable analytical product will do. That’s why we offer the Supelco® portfolio of reference materials, including our Cerilliant® ready-to-use solution standards. Whatever your needs, our portfolio is always fit for purpose, ensuring your results are accurate, precise and reproducible, and your systems fully certified. Our comprehensive portfolio, developed by analytical chemists for analytical chemists, covers a broad range of analytical solutions, and every product is meticulously quality-controlled to maintain the integrity of your testing protocols. And with Supelco® scientists dedicated to your analytical applications, the expertise you need is always on hand. 3 Amphetamines Amphetamines have an extended history of abuse seen throughout the world. This drug class includes amphetamine and its derivatives, which are predominantly central nervous system stimulants responsible for increasing alertness and focus, improving mood, decreasing fatigue, and reducing appetite. Many amphetamines are legally used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy and depression or are prescribed as weight-loss drugs. Amphetamines can also produce euphoria and psychedelic effects and are therefore sold as “designer drugs” on the illicit drug market. Amphetamines have a high potential for abuse and psychological addiction. Cat. No. Product Description Amphetamines A-007-1ML (±)-Amphetamine, 1.0 mg/mL in methanol A-013-1ML (±)-Amphetamine-D5 (deuterium label on side chain), 1.0 mg/mL in methanol M-013-1ML (±)-MDMA, 1.0 mg/mL in methanol M-029-1ML (±)-MDMA-D5, 1.0 mg/mL in methanol M-009-1ML (±)-Methamphetamine, 1.0 mg/mL in methanol M-060-1ML (±)-Methamphetamine-D11, 1.0 mg/mL in methanol H-136-1ML 4-Hydroxyamphetamine HCl, 1.0 mg/mL (as free base) in methanol H-133-1ML 4-Hydroxyamphetamine-D5 HBr, 100 μg/mL (as free base) in methanol F-056-1ML Fenproporex HCl, 1 mg/mL (as free base) in methanol F-057-1ML Fenproporex-D5 HCl, 100 μg/mL in methanol P-127-1ML Phendimetrazine tartrate, 1.0 mg/mL in methanol P-132-1ML Phendimetrazine-D5 HCl, 100 mg/mL (as free base) in methanol P-128-1ML Phenmetrazine HCl, 1mg/mL in methanol P-129-1ML Phenmetrazine-D5 HCl, 100 µg/mL (as free base) in methanol New 4 Novel Psychoactive Substances GC Analysis of Basic Drugs using an Equity®-5 Column 1. Amphetamine 10. Cocaine Amphetamine: 2. Methamphetamine 11. Desipramine Excellent Response 5 6 3. Nicotine 12. Codeine and Peak Symmetry 4. Caffeine 13. Morphine 3 9 5. Diphenhydramine 14. Diazepam 8 6. Lidocaine 15. Heroin 7. Phenobarbital 16. Fentanyl 10 8. Methadone 9. Amitriptyline 4 14 1 Key Resolutions 12 Conditions 7 Achieved 2 11 16 column Equity®-5, 30 m x 0.25 mm I.D., 0.25 µm 15 (28089-U) oven 45 °C (2 min), 25 °C/min to 110 °C, 13 15 °C/min to 200 °C, 6 C/min to 280 °C (3 min) 5 10 15 20 carrier gas helium, 40 psi for 0.2 min then 0.7 mL/min Min constant flow sample ~15 ng on-column of a 16-component drug standard injection 0.3 µL pulsed splitless @ 50 mL/min (0.5 min) liner 2 mm I.D., splitless inj. temp. 250 °C MSD 325 °C interface scan range m/z = 40-450 HPLC Analysis of Amphetamine and Methamphetamine Enantiomers on Astec® CHIROBIOTIC® V2 column 1 1. S(+)-Amphetamine 2 Resolution of the enantiomers of methamphetamine and 2. R(-)-Amphetamine amphetamine is of clinical interest for two reasons: they 3. S(+)-Methamphetamine exhibit different physiological effects, and it is a means to 4. R(-)-Methamphetamine 3 distinguish between legal and illicit sources of the drugs. 4 Shown here is the rapid and efficient resolution of all four enantiomers on an Astec® CHIROBIOTIC® V2 column Conditions column Astec® CHIROBIOTIC® V2, 25 cm x 4.6 mm I.D., 5 µm (15024AST) column 40 °C temp. mobile [A] methanol; [B] water; [C] acetic acid; phase [D] ammonium hydroxide; (95:5:0.1:0.02, A:B:C:D) flow rate 1 mL/min 02468101214 pressure 840 psi (58 bar) Min sample 100 µg/mL each enantiomer in methanol injection 5 µL detector UV, 205 nm To read more visit us at SigmaAldrich.com/amphetamines-chiral-HPLC 5 Analgesics (non-opioid) Non-opioid analgesics include non-steroidal anti- inflammatory drugs (NSAIDs), selective COX-2 inhibitors, and acetaminophen. NSAIDs have potent anti-inflammatory, analgesic and antipyretic activity, and are particularly effective in the management of musculoskeletal pain. Cat. No. Product Description Cat. No. Product Description Analgesics (non-opioid) D-110-1ML N-Desmethyl-cis-tramadol-D3 HCl, 100 μg/mL (as free base) in methanol M-007-1ML (±)-Methadone, 1.0 mg/mL in methanol N-089-1ML Normeperidine, 1.0 mg/mL in methanol M-021-1ML (±)-Methadone-D3, 1.0 mg/mL in methanol N-083-1ML Normeperidine-D4, 1.0 mg/mL in methanol M-089-1ML (±)-Methadone-D9, 1.0 mg/mL in methanol D-058-1ML O-Desmethyl-cis-tramadol-D6, 100 μg/mL A-064-1ML Acetaminophen, 1.0 mg/mL in methanol (as free base) in methanol P-917-1ML Acetaminophen-D4, 1.0 mg/mL in methanol T-058-1ML Tapentadol HCl, 1.0 mg/mL (as free base) in methanol P-909-1ML Acetaminophen-D4, 100 μg/mL in methanol A-113-1ML AH-7921 HCl 1.0 mg/mL (as free base) in methanol T-059-1ML Tapentadol-D3 HCl, 100 μg/mL (as free base) in methanol A-114-1ML AH-7921-D3 HCl, 100 μg/mL (as free base) in methanol T-067-1ML Tapentadol-D3-ß-D-glucuronide,
Load more

Recommended publications
  • Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materialsd
    Recommended methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Photo credits:UNODC Photo Library; UNODC/Ioulia Kondratovitch; Alessandro Scotti. Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Synthetic Cathinones in Seized Materials (Revised and updated) MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2020 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/49/REV.1 Original language: English © United Nations, March 2020. All rights reserved, worldwide. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • The 2014 Prohibited List International Standard
    The World Anti-Doping Code THE 2014 PROHIBITED LIST INTERNATIONAL STANDARD Version 2.0 (revised 2014 version) The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 September 2014 The revised 2014 Prohibited List 17 May 2014 THE 2014 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 September 2014 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α- androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol;
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
    [Show full text]
  • Structure-Cytotoxicity Relationship Profile of 13 Synthetic Cathinones In
    Neurotoxicology 75 (2019) 158–173 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells T ⁎ Jorge Soaresa, , Vera Marisa Costaa, Helena Gasparb,c, Susana Santosd,e, Maria de Lourdes Bastosa, ⁎ Félix Carvalhoa, João Paulo Capelaa,f, a UCIBIO, REQUIMTE (Rede de Química e Tecnologia), Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Portugal b BioISI – Instituto de Biossistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, Portugal c MARE - Centro de Ciências do Mar e do Ambiente, Escola Superior de Turismo e Tecnologia do Mar, Instituto Politécnico de Leiria, Portugal d Centro de Química e Bioquímica (CQB), Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Portugal e Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Portugal f FP-ENAS (Unidade de Investigação UFP em Energia, Ambiente e Saúde), CEBIMED (Centro de Estudos em Biomedicina), Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal ARTICLE INFO ABSTRACT Keywords: Synthetic cathinones also known as β-keto amphetamines are a new group of recreational designer drugs. We Synthetic cathinones aimed to evaluate the cytotoxic potential of thirteen cathinones lacking the methylenedioxy ring and establish a Classical amphetamines putative structure-toxicity profile using differentiated SH-SY5Y cells, as well as to compare their toxicity to that Cytotoxicity of amphetamine (AMPH) and methamphetamine (METH). Cytotoxicity assays [mitochondrial 3-(4,5-dimethyl-2- SH-SY5Y cells thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction and lysosomal neutral red (NR) uptake] per- Structure-toxicity relationship formed after a 24-h or a 48-h exposure revealed for all tested drugs a concentration-dependent toxicity.
    [Show full text]
  • Immediate Action New Tests and Test Updates
    Effective Date: Monday, August 26, 2013 New Tests and Test Updates Immediate Action In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, August 26, 2013 New Tests - Tests recently added to the NMS Labs test menu. New Tests are effective immediately. Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements. Discontinued Tests - Tests being discontinued with alternate testing suggestions. Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases. If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes. The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document. NMS LABS 3701 Welsh Road Willow Grove, PA 19090 www.NMSLabs.com Page 1 of 76 Effective Date: Monday, August 26, 2013 New Tests and Test Updates Test Test Name New Test Method / Specimen Stability Scope Units Reference Discontinue
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Supplementary Material Portable Near Infrared Spectroscopy (Micronir
    Electronic Supplementary Material (ESI) for Analytical Methods. This journal is © The Royal Society of Chemistry 2018 Supplementary Material Portable near infrared spectroscopy (microNIR) applied to abuse drugs and medicines analyzes Radigya M. Correia,a Eloilson Domingos,a Flavia Tosato,a Nayara A. dos Santos,a Julia de A. Leite,a Mayara da Silva,a Marcelo C. A. Marcelo,b Rafael S. Ortiz,c,d Paulo R. Filgueiras,a Wanderson Romãoa,d,e* a Laboratório de Petroleômica e Química Forense, Departamento de Química, Universidade Federal do Espírito Santo, 29075-910 Vitória – ES, Brazil. b Instituto de Química, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil. c Setor Técnico-Científico, Superintendência Regional do Departamento de Polícia Federal no Rio Grande do Sul, Brazil. d Instituto Nacional de Ciência e Tecnologia Forense (INCT Forense), Brazil. e Instituto Federal do Espírito Santo, 29106-010 Vila Velha – ES, Brazil. Table 1S. Active ingredients identified by CG-MS analysis Samples Active ingredient identified by CG-MS Amphetamine, FA, Methamphetamine, MDMA, and C1 2CB C2 Amphetamine, and caffeine C3 Amphetamine, and caffeine C4 MDMA C5 MDMA C6 MDMA C7 MDMA C8 Ethylone, and Ketamine C9 Ethylone, and Ketamine C10 Ethylone, and Ketamine C11 MDMA C12 MDMA C13 MDMA C14 MDMA C15 MDMA C16 MDMA C17 MDMA C18 MDMA, and Ethylone C19 MDA Table 2S.. m/z values, mass error (ppm), DBE, empirical formula and proposed structures for the signals detected from PS(+)MS analysis for designer drugs samples. Proposed measured
    [Show full text]
  • Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings
    medical sciences Review Possible Mechanisms Involved in the Vasorelaxant Effect Produced by Anorexigenic Drugs in Rat Aortic Rings Daniela García-Alonso 1, Dan Morgenstern-Kaplan 1 , Ariel Cohen-Welch 1 , Jair Lozano-Cuenca 2 and Jorge Skiold López-Canales 2,* 1 Centro de Investigación en Ciencias de la Salud Anáhuac (CICSA), Universidad Anáhuac México Campus Norte, Mexico City 52786, Mexico; [email protected] (D.G.-A.); [email protected] (D.M.-K.); [email protected] (A.C.-W.) 2 Department of Physiology and Cellular Development, National Institute of Perinatology, Mexico City 11000, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +52-55-5520-9900 (ext. 270, 340) Received: 8 February 2019; Accepted: 22 February 2019; Published: 27 February 2019 Abstract: Anorexigenics are compounds capable of reducing or suppressing appetite. Their three main types act on different neurotransmitters, either norepinephrine, serotonin or a combination of both. Among the drugs that act on norepinephrine are fenproporex, amfepramone and clobenzorex. Derivatives of the thyroid hormone triiodothyronine have also been associated with weight loss and used as a controversial treatment for obesity, despite their known cardiovascular side effects. Recent data suggest a possible vasodilating effect for these four substances that might be beneficial in a subset of patients. Herein we performed a systematic review of the literature (with emphasis on recent reports) to determine the implications and mechanisms of the vasodilating effects of some anorectics, specifically fenproporex, clobenzorex, amfepramone and triiodothyronine. Data analysis showed these four drugs to be vasodilating agents for rat aortic rings. The different mechanisms of action include endothelium-dependent vasodilation via activation of the NO-cGMP-PKG pathway and the opening of calcium-activated potassium channels.
    [Show full text]
  • Conversion Factors Psychotropics
    Green List 30th edition, 2019 Annex to the annual statistical report on International Narcotics Control Board psychotropic substances (form P) List of Psychotropic Substances under International Control In accordance with the Convention on Psychotropic Substances of 1971 UPDATES • Inclusion of 5 new substances in Schedule II : ADB-CHMINACA, ADB-FUBINACA, CUMYL- 4CN-BINACA, N-ETHYLNORPENTYLONE and FUB-AMB. The Green List has been prepared by the International Narcotics Control Board to assist Governments in completing the annual statistical report on psychotropic substances (form P) and the quarterly statistics of imports and exports of substances in Schedule II of the Convention on Psychotropic Substances of 1971 (form A/P). For information on the names used for substances under international control and preparations containing such substances, as well as on chemical and structural formulae and other techni cal information, see Multilingual Dictionary of Narcotic Drugs and Psychotropic Substances under International Control .1 __________________ 1 United Nations publication, Sales No. M.06.XI.16. V.19-08673 (E) *1908673* The Green List is divided into three parts: Part one. Substances in Schedules I, II, III and IV of the Convention on Psychotropic Substances of 1971; Part two. Pure drug content of bases and salts of psychotropic substances under international control; Part three. Prohibition of and restrictions on export and import pursuant to article 13 of the Convention on Psychotropic Substances of 1971. 2 Part one. Substances in Schedules I, II, III and IV of the Convention on Psychotropic Substances of 1971 Psychotropic substances under international control are presented in the schedules below. Where an international non-proprietary name (INN) is available for a substance, that INN is given in the left -hand column.
    [Show full text]